All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

An mTOR-I based immunosuppression following renal transplantation remains ill accepted. Latest OPTN data indicate a continuous decline of mTOR-I use of currently below 5% \[[@pone.0234396.ref001]\]. Undisputed benefits for renal function and development of skin tumors \[[@pone.0234396.ref002], [@pone.0234396.ref003]\] are opposed by an array of side effects and limited tolerability \[[@pone.0234396.ref004], [@pone.0234396.ref005]\]. Furthermore, immunological potency when administered as main basic immunosuppressant was accused to lack behind Calcineurininhibitors (CNI) \[[@pone.0234396.ref005]\]. Despite all progress that has been made throughout the past decades graft survival remains limited. Ten year graft loss of deceased donor renal transplants has to be expected in 51.6% \[[@pone.0234396.ref001]\].

In trying to avoid the negative while preserving the positive effects of the mTOR-Is various conversion strategies had been studied \[[@pone.0234396.ref003], [@pone.0234396.ref006]--[@pone.0234396.ref008]\]. Pursuing a similar rationale many trials investigated the combination of mTOR-Is and CNIs \[[@pone.0234396.ref006], [@pone.0234396.ref009]--[@pone.0234396.ref011]\].

Irrespective of the trial design reliable "long-term" data are scarce. Follow-up universally stops well before the known half-lives of the grafts. And registry data which are preferably used to step in to close this gap of information are helpful but less accurate.

A growing body of evidence indicates that development of de novo donor specific antibodies (dnDSA) is a strong risk factor for the graft survival \[[@pone.0234396.ref012]--[@pone.0234396.ref014]\]. The incidence of dnDSAs is increasing over time and is thought to be around 20--30% after 5 years of transplantation with implications for the occurrence of humoral rejection \[[@pone.0234396.ref015]\]. The question if dnDSAs occur more often under mTOR-Is compared to CNIs remains unclear. Patients from the ZEUS and HERACLES trials showed a higher percentage of dnDSA after conversion to EVRL (23%) compared to the CsA (11%) \[[@pone.0234396.ref016]\]. This could not be confirmed by the TRANSFORM nor the PostConcept-Study \[[@pone.0234396.ref017], [@pone.0234396.ref018]\].

In 2006, we initiated the randomized controlled multicenter "SMART"-Trial where an early switch from CsA to SRL after renal transplantation was evaluated. One- and three-year results have been published \[[@pone.0234396.ref003], [@pone.0234396.ref019]\]. Here, we deliver "long-term" data (\~ 10 years) of this trial on donor-specific antibodies, transplant function, graft and patient survival.

Materials and methods {#sec006}
=====================

Trial design {#sec007}
------------

This trial was conducted according to GCP guidelines and the declaration of Helsinki and was approved by the local ethics committee of the Ludwig-Maximilian's university (LMU in Munich) and the ethics committees of the participating centers (EudraCT-Nr. 2013-004956-39).

This trial was a "follow-up" analysis of a prospective randomized controlled multicenter trial following renal transplantation (SMART-Trial; [Controlled-trials.com](http://Controlled-trials.com), ISRCTN no. 74429508). For the original trial none of the transplant donors were from a vulnerable population and all donors or next of kin provided written informed consent that was freely given.

The original design, 12- and 36-months data have been described in detail elsewhere \[[@pone.0234396.ref003], [@pone.0234396.ref019]\]. In short, n = 140 patients were started on a regular Cyclosporine A (CsA-) containing regimen and randomized to either remain on CsA or be switched to a CNI-free Sirolimus (SRL)-based immunosuppressive regimen between day 10--24 after transplantation ([Fig 1](#pone.0234396.g001){ref-type="fig"}). CsA was started in all patients within 24 hours after transplantation along with oral MMF. All patients received induction therapy with ATG (Fresenius) and 500 mg methylprednisolone intraoperatively and a maintenance dose thereafter according to the local practice of the participating center. SRL was initiated with a loading dose of up to 0.1 mg/kg followed by 2 to 4 mg/d once daily, aiming for an initial target trough level of 8 to 12 ng/mL. At this time, CsA was reduced by 50% and eliminated 3 days later. After 3 months, SRL was tapered to achieve target levels of 5 to 10 ng/ml.

![Flowchart.\
This is a follow-up trial of the randomized, controlled multicenter SMART-Trial (area shown with dashed lines). 12- and 36 months' data have already been published. The original ITT population consisted of n = 140 patients. Data on all patients were used for graft and patient survival analysis. n = 74 (SRL n = 39 and CsA n = 35) appeared to a follow up visit of which n = 71 (SRL n = 38 and CsA n = 33) had still a functioning graft and could thus be included for this follow-up trial for antibody screening and transplant function tests on average 104.2+8.8 months after the transplantation.](pone.0234396.g001){#pone.0234396.g001}

Eligibility criteria {#sec008}
--------------------

All patients originally randomized to the SMART trial (ITT-cohort) were included and contacted by mail using a study plan including a consent form. In case patients did not respond they were contacted via telephone in the next step. All patients were \> 18 years of age. One cohort consisted of n = 71 patients with still functioning graft who personally appeared to a control visit into the transplant centers. These patients delivered the blood samples for donor specific antibody- and current kidney function testing. Data on all SMART ITT-patients (n = 140) were gathered by retrospective chart review and contact of the primary care physician as well as the patients themselves. These data were used for the analysis of graft and patient survival.

Primary objective {#sec009}
-----------------

Incidence and characterization of donor specific antibodies.

Secondary objectives {#sec010}
--------------------

Patient and graft survival, transplant function, acute rejection episodes, incidence of malignancy and infection, therapy discontinuations, adverse events.

HLA-antibody testing {#sec011}
--------------------

All samples were sent to and processed in the Laboratory of Immunogenetics, Ludwig-Maximilian's-University in Munich, Germany.

Serum samples were screened for HLA antibodies using Luminex-technology with LABScreen Single Antigen Beads (SAB) (One Lambda, Canoga Park, CA, USA). The C1q-binding capacity of antibodies was also tested by C1q-SAB assay (One Lambda, Canoga Park, CA, USA). Donor specificity of HLA-antibodies was assumed for a MFI cut-off higher than 1000. All tests were performed according to the manufacturer's specifications.

Statistics {#sec012}
----------

Data are summarized by descriptive statistics based on mean and standard deviation for continuous parameters or absolute and relative frequencies for categorical variables. Comparisons between groups were performed by use of the nonparametric Wilcoxon rank sum test for continuous variables and Fisher's exact test for the analysis of contingency tables. All p-values were two-sided, and a p-value \< 0.05 was considered statistically significant.

Patient and graft survival (and other time to event data) were calculated according to the Kaplan Meier method and compared between randomized groups using the log-rank test. Actuarial 5 and 10-year survival rates were calculated based on the Life Table Method. A cox model was applied for the estimation of hazard ratios. Transplant function was further assessed by comparing the changes from month 3 after the transplantation to the end of follow-up. For these, mean changes from baseline were analyzed using a maximum likelihood (ML)‐based repeated measures approach. Analyses include the fixed, categorical effects of treatment, and the continuous time point as well as their interaction. A first-order autoregressive covariance structure was applied to model the within‐patient errors. Occurrence of de novo HLA antibodies were compared between treatment arms by use of the site adjusted Mantel-Haenszel test. Univariate analysis of potential factors influencing the development of DSA was performed using Fisher's exact test with a threshold of p \< 0.1. Continuous parameters were dichotomized based on cut-points evaluated by ROC analysis using the Youden index. Variables for analysis were selected when there was a frequency of at least 5.

Statistical analyses were done using SAS for windows, version 9.3 (SAS Institute Inc., Cary, NC, USA).

Results {#sec013}
=======

Demographics {#sec014}
------------

Of the n = 140 patients randomized to the original SMART-trial, n = 71 patients (n = 38 SRL; n = 33 CsA) presented for study examination on average 8.7 years after the transplantation (104±9.5 months SRL vs. 104±8.1 months CsA; p = 0.89). Age, height, weight, gender, ethnicity, underlying condition showed no significant differences between the groups ([Table 1](#pone.0234396.t001){ref-type="table"}). The immunological risk as defined by the panel reactive antibodies (PRAs) pre-Tx was similar (0% \> 0 SRL vs. 3.0% \> 0 CsA, p = 0.46). Neither was there a difference with respect to HLA mismatch (2.1±1.5 SRL vs. 2.4±1.5 CsA, p = 0.44).

10.1371/journal.pone.0234396.t001

###### Demographics.

![](pone.0234396.t001){#pone.0234396.t001g}

                              SMART Population   Long Term Follow Up (SMART-DSA)                                    
  --------------------------- ------------------ --------------------------------- -------- ----------- ----------- --------
  Recipient Age (yrs)         47.0±10.8          47.1±11.1                         0.9418   45.3±10.6   45.4±11.3   0.8310
  Height (cm)                 171.0±8.8          172.4±9.0                         0.2769   171±7.8     171±8.5     0.6031
  Weight (kg)                 71.0±12.5          76.3±12.1                         0.0158   69.5±12.2   74.2±11.0   0.0967
  Male                        45 (65.2)          50 (70.4)                         0.5882   23 (60.5)   23 (69.7)   0.4636
  Polycystic Kidney Disease   10 (14.5)          8 (11.3)                          0.6205   4 (10.5)    3 (9.1)     1.0000
  Glomerulonephritis          25 (36.2)          30 (42.3)                         0.4930   13 (34)     11 (33)     1.0000
  PRA \> 0                    1 (1.4)            2 (2.8)                           1.0000   0 (0.0)     1 (3.0)     0.4648
  CIT (hrs)                   12.1±5.7)          13.0±7.0                          0.5228   11.0±5.9    12.5±6.9    0.4122
  HLA-Mismatch                2.8±1.2            2.9±1.2                           0.6533   2.1±1.5     2.4±1.5     0.4445
  1st Transplant              62 (89.9)          67 (94.4)                         0.3628   34 (89.5)   32 (97.0)   0.3633
  CMV-Status Donor+/rec-      10 (14.5)          10 (14.4)                         1.0000   6 (15.8)    5 (15.2)    1.0000
  DGF, Dialysis \>1           15 (21.7)          19 (26.8)                         0.5565   6 (15.8)    9 (27.3)    0.2600
  Donor Age (yrs)             46.9±14.3          47.1±14.3                         0.9451   46.5±13.6   45.3±14.0   0.6736
  Living Donation             8 811.6)           7 (9.9)                           0.7901   6 (15.8)    2 (6.1)     0.2705
  Ethnicity Caucasian         68 (98.6)          80 (98.6)                         1.0000   38 (100)    33 (100)    1.0000
  Therapy discontinuations    46 (66.7)          24 (33.8)                         0.0002   26 (68.4)   11 (33.3)   0.0043

Patients from both treatment arms did not differ significantly regarding underlying condition, immunization status pre transplant, DGF or specifics to the donor. There were significantly more therapy discontinuations in the SRL arm.

Altogether, n = 69 patients could not be included in the DSA-analysis (n = 31 SRL vs. n = 38 CsA, p = 0.31.; [Fig 1](#pone.0234396.g001){ref-type="fig"}) for the following reasons ([Table 2](#pone.0234396.t002){ref-type="table"}): n = 19 had already died (n = 11 SRL vs. n = 8 CsA; p = 0.47), n = 13 patients were lost to follow-up (n = 4 SRL vs. n = 9 CsA; p = 0.24), n = 18 (n = 7 SRL vs. n = 11 CsA; p = 0.45) denied participation in this trial and n = 19 had lost transplant function (n = 9 SRL vs. n = 10 CsA; p = 1.0).

10.1371/journal.pone.0234396.t002

###### Screening failures.

![](pone.0234396.t002){#pone.0234396.t002g}

                      SRL (N = 69) n (%)   CsA (N = 71) n (%)   P-value
  ------------------- -------------------- -------------------- ---------
  Death               11 (15.94)           8 (11.27)            0.4668
  Loss of function    9 (13.04)            10 (14.08)           1.0000
  No consent          7 (10.14)            11 (15.49)           0.4506
  Lost to follow-up   4 (5.80)             9 (12.68)            0.2442
  All                 31 (44.93)           38 (53.52)           0.3171

There were no significant differences to screening failures in both treatment arms.

Upon presentation only n = 12 (31.6%) patients of the SRL arm and n = 22 (66.7%) of the CsA arm were still on the original immunosuppressant (p = 0.004, [Table 1](#pone.0234396.t001){ref-type="table"}). Most patients had been switched to Tacrolimus in the meantime ([S1](#pone.0234396.s012){ref-type="supplementary-material"} & [S2](#pone.0234396.s013){ref-type="supplementary-material"} Tables).

Development of de novo HLA antibodies {#sec015}
-------------------------------------

In n = 50 pts. (70%) no HLA-antibodies were found at the study visit ([Table 3](#pone.0234396.t003){ref-type="table"}). In n = 21 pts. (30%) HLA-antibodies were positive (n = 9 (24%) SRL vs. n = 12 (36%) CsA; p = 0.16). C1q-binding ability could be confirmed in n = 10 of these HLA-antibody positive pts. (n = 6 (15.8%) SRL vs. n = 4 (12.1%) CsA; p = 0.64). HLA-antibodies directed against the donor specificity were found in n = 14 pts (20%) (n = 5 (13.2%) SRL vs. n = 9 (27.3%) CsA; p = 0.09). The majority of DSA was directed against HLA-class II antigens. In the non-donorspecific HLA-antibody positive patients we found even distribution of HLA-class I and II.

10.1371/journal.pone.0234396.t003

###### Analysis of de novo HLA antibodies.

![](pone.0234396.t003){#pone.0234396.t003g}

                    SRL (N = 38) n (%)   CsA (N = 33) n (%)   P-value
  ----------------- -------------------- -------------------- ---------
  Dn HLA-Ab         9 (23.7)             12 (36.4)            0.1616
      Class I       6 (15.8)             4 (12.1)             0.4772
      Class II      6 (15.8)             9 (27.3)             0.2241
      C1q-binding   6 (15.8)             4 (12.1)             0.6371
  DSA               5 (13.2)             9 (27.3)             0.0968
      Class I       2 (5.3)              2 (6.1)              0.8484
      Class II      4 (10.5)             8 (24.2)             0.1198
      C1q-binding   4 (10.5)             3 (9.1)              0.7274
  NDSA              8 (21.1)             6 (18.2)             0.7553
      Class I       6 (15.8)             4 (12.1)             0.4772
      Class II      4 (10.5)             3 (9.1)              0.6253
      C1q-binding   4 (10.5)             3 (9.1)              0.8932

No differences for the treatment groups could be detected regarding development of dn HLA-Abs.

Correlation of HLA-antibodies with transplant function and acute rejection {#sec016}
--------------------------------------------------------------------------

Renal function as measured by eGFR was not significantly different in pts. with DSA (DSA pos. 57.72±39.45 ml/min vs. DSA neg. 59.70±18.88 ml/min; p = 0.12) ([Table 4](#pone.0234396.t004){ref-type="table"}). Renal function was significantly reduced in the presence of antibodies against HLA-class II (HLA II Abs: 46.18±17.22 ml/min vs. no HLA II Abs: 62.82±24.42 ml/min; p = 0.01).

10.1371/journal.pone.0234396.t004

###### Correlation of DSA and Class II HLA antibodies with transplant function.
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  Renal Function                         mean±SD        mean±SD       P-value
  -------------------------------------- -------------- ------------- ---------
  DSA                                    Yes (n = 14)   No (n = 57)   
      eGFR (Nankivell, mL/min/1.73 m2)   57.72±39.45    59.70±18.88   0.1203
      sCr (mg/dl)                        2.02±0.98      1.59±0.69     0.0564
  Class II                               Yes (N = 15)   No (N = 56)   
      eGFR (Nankivell, mL/min/1.73 m2)   46.18±17.22    62.82±24.42   0.0101
      SCr (mg/dl)                        2.17±0.95      1.55±0.65     0.0063

Transplant function was significantly impaired when DSA or class II HLA Abs were found.

Risk for de novo DSA development {#sec017}
--------------------------------

Univariate analysis identified only the recipient age \< 39 years (OR: 3.07; 0.92--10.29; p = 0.09; [Table 5](#pone.0234396.t005){ref-type="table"}) as a risk factor for de novo DSA development. Male gender (OR: 4.06; 0.83--19.86; p = 0.12), living donation (OR: 2.84; 0.59--13.66; p = 0.19), low ATG induction (OR: 2.84; 0.59--13.66; p = 0.19) and an impaired transplant function (OR: 5.07; 0.61--42.03; p = 0.16) were not significant.

10.1371/journal.pone.0234396.t005

###### Univariate analyses on the risk for developing *de novo* DSA.
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                                                         Univariate analysis                 
  ------------------------------------------------------ --------------------- ------------- --------
  Male                                                   4.06                  0.83--19.86   0.1163
  Re-transplantation                                     3.00                  0.45--19.97   0.2537
  Rec. Age ≤ 39                                          3.07                  0.92--10.29   0.0995
  Living donor                                           2.84                  0.59--13.66   0.1864
  CIT \> 11h                                             0.43                  0.13--1.46    0.2351
  Low ATG induction                                      2.84                  0.59--13.66   0.1864
  Donor age ≤ 57                                         4.23                  0.51--35.31   0.2731
  [\*](#t005fn001){ref-type="table-fn"}SCr-Tk+7 ≥ 1.27   5.07                  0.61--42.03   0.1625
  Banff 4                                                1.76                  0.53--5.87    0.3587
  Ciclosporin                                            2.47                  0.74--8.33    0.2311

\* Serum Creatinine 7 days after the timepoint of conversion

Transplant function {#sec018}
-------------------

Transplant function improved under SRL starting with the randomization and remained improved until the latest measurement 104±9 months after the transplantation ([Fig 2](#pone.0234396.g002){ref-type="fig"}; [Table 6](#pone.0234396.t006){ref-type="table"}; SRL 64.37±26.44 ml/min/1.73 m^2^ vs. CsA 53.19±19.83 ml/min/1.73 m^2^; p = 0.04). Measurements by Cockcroft-Gault (SRL 56.03 ± 18.62 ml/min/1.73 m^2^ vs. CsA 48.98 ± 19.93 ml/min/1.73 m^2^; p = 0.12), MDRD (SRL 53.42 ± 21.28 ml/min/1.73 m2 vs. CsA 45.92 ± 20.87 ml/min/1.73 m2; p = 0.11) and CKD-EPI (SRL 53.86 ± 21.64 ml/min/1.73 m2 vs. CsA 45.78 ± 20.84 ml/min/1.73 m2; p = 0.11) missed significance. Analysis of those patients who had remained on the original therapy showed a similar picture with an improved transplant function under SRL.

![Transplant function over time.\
Transplant function was significantly better in the SRL treatment group at long term follow-up. Data shown are median values and interquartile ranges starting from randomization in patients who completed the DSA follow up at a median of 104 ± 9 months after transplantation. Significant p-values for the Wilcoxon rank sum test are marked with an asterisk.](pone.0234396.g002){#pone.0234396.g002}

10.1371/journal.pone.0234396.t006

###### Transplant function at long term follow up (104± 8.8 months after Tx).
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                                          SRL             CsA             p-Value
  --------------------------------------- --------------- --------------- ---------
  **ITT population**                                                      
      sCr (mg/dL))                        (n = 38)        (n = 33)        
          Mean ± SD                       1.54 ± 0.71     1.83 ± 0.81     0.0720
      eGFR (Nankivell, mL/min/1.73m^2^)   (n = 38)        (n = 32)        
          Mean ± SD                       64.37 ± 26.44   53.19 ± 19.83   0.0444
      eCrCl (Cockroft Gault, mL/min)      (n = 38)        (N = 32)        
          Mean ± SD                       56.03 ± 18.62   48.98 ± 19.93   0.1211
      eGFR (MDRD, mL/ mL/min/1.73m^2^)    (n = 38)        (n = 33)        
          Mean ± SD                       53.42 ± 21.28   45.92 ± 20.87   0.1053
      eGFR (CKD-EPI, mL/ mL/min/1.73m2)   (n = 38)        (n = 33)        
          Mean±SD                         53.86±21.64     45.78±20.84     0.1053
  **On therapy population**                                               
      sCr (mg/dL))                        (n = 12)        (n = 22)        
          Mean ± SD                       1.39 ± 0.49     1.74 ± 0.63     0.0937
      eGFR (Nankivell, mL/min/1.73m^2^)   (n = 12)        (n = 21)        
          Mean ± SD                       66.00 ± 15.25   52.83 ± 19.71   0.0314
      eCrCl (Cockroft Gault, mL/min)      (n = 12)        (n = 21)        
          Mean ± SD                       57.05 ± 16.00   47.71 ± 19.58   0.1117
      eGFR (MDRD, mL/ mL/min/1.73m^2^)    (n = 12)        (n = 22)        
          Mean ± SD                       55.33 ± 17.74   45.34 ± 20.43   0.0869
      eGFR (CKD-EPI, mL/ mL/min/1.73m2)   (n = 12)        (n = 22)        
          Mean±SD                         55.99±18.68     44.84±19.57     0.0869

Transplant function as measured by Nankivell was significantly improved for the SRL treatment group. Patients who had remained on SRL also showed a significant benefit compared to the CsA treatment.

GFR comparison of month 3 after Tx to most recently (104±9 months) revealed a more pronounced deterioration in the CsA group (MDRD: -0.87 ± 14.58 ml/min/1.73 m^2^ SRL vs. -8.26 ± 18.04 ml/min/1.73 m^2^ CsA; p = 0.07; CKD-EPI: -2.08 ± 15.39 ml/min/1.73 m^2^ SRL vs. -9.91 ± 18.59 ml/min/1.73 m^2^ CsA; p = 0.06; [Table 7](#pone.0234396.t007){ref-type="table"}).

10.1371/journal.pone.0234396.t007

###### Change in eGFR from month 3 to 104±8.8 months post transplantation.
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                                            SRL             CsA              p-Value
  ----------------------------------------- --------------- ---------------- ---------
  **ITT population**                                                         
      Δ-sCr (mg/dL))                        (n = 38)        (n = 33)         
          Mean ± SD                         -0.01 ± 0.57    0.27 ± 0.68      0.1154
      Δ-eGFR (Nankivell, mL/min/1.73m^2^)   (n = 38)        (n = 32)         
          Mean ± SD                         0.17 ± 14.31    -6.46 ± 18.12    0.1733
      Δ-eCrCl (Cockroft Gault, mL/min)      (n = 38)        (n = 32)         
          Mean ± SD                         -3.61 ± 14.17   -11.01 ± 18.77   0.0760
      Δ-eGFR (MDRD, mL/ mL/min/1.73m^2^)    (n = 38)        (n = 33)         
          Mean ± SD                         -0.87 ± 14.58   -8.26 ± 18.04    0.0677
      Δ-eGFR (CKD-EPI, mL/ mL/min/1.73m2)   (n = 38)        (n = 33)         
          Mean±SD                           -2.08±15.39     -9.91±18.59      0.0643
  **On therapy population**                                                  
      Δ-sCr (mg/dL))                        (n = 12)        (n = 22)         
          Mean ± SD                         -0.12 ± 0.60    0.22 ± 0.51      0.2269
      Δ-eGFR (Nankivell, mL/min/1.73m^2^)   (n = 12)        (n = 21)         
          Mean ± SD                         3.33 ± 14.38    -7.26 ± 20.13    0.2385
      Δ-eCrCl (Cockroft Gault, mL/min)      (n = 12)        (n = 21)         
          Mean ± SD                         -2.20 ± 14.46   -12.23 ± 20.51   0.1393
      Δ-eGFR (MDRD, mL/ mL/min/1.73m^2^)    (n = 12)        (n = 22)         
          Mean ± SD                         1.22 ± 15.66    -9.29 ± 19.64    0.1653
      Δ-eGFR (CKD-EPI, mL/ mL/min/1.73m2)   (n = 12)        (n = 22)         
          Mean±SD                           -0.26±16.37     -11.18±20.08     0.2318

For patients from the CsA treatment group all measurements showed a deterioration of the transplant function over this observation period. Under SRL, transplant function remained more stable with either no or minimal change of function compared to month 3. ΔsCr: delta serum creatinine, ΔeCrCl: delta estimated creatinine clearance, ΔeGFR: delta estimated glomerular filtration rate (Differences: follow up month 3).

Mixed model longitudinal analysis of renal function with fixed effects of randomized treatment, time and the combination of time and treatment confirmed a significant advantage of the SRL group starting at 3 months after transplantation ([S3 Table](#pone.0234396.s014){ref-type="supplementary-material"}).

Patient survival {#sec019}
----------------

Looking at the original ITT cohort of n = 140 patients, Kaplan-Meier curves did not show a difference for the patient survival ([Fig 3](#pone.0234396.g003){ref-type="fig"}; p = 0.67; HR 1.225 (95% CI: 0.483--3.104)). Actuarial five-year survival was on average 94.2% (SRL: 95.5% vs. CsA 92.9%) and 82.8% after ten years (SRL: 83.6% vs. CsA 82.1%). Under SRL n = 11 patients (16%) died compared to n = 8 (11%) in the CsA arm (p = 0.47).

![Kaplan-Meier curve on patient survival.\
Event rates were 10/69 in the SRL and 8/71 in the CsA Group. Hazard ratio for SRL (95%CI): 1.225 (0.483--3.104).](pone.0234396.g003){#pone.0234396.g003}

Causes of death were: n = 3 cardiovascular (2 SRL vs. 1 CsA), n = 3 malignancy (2 SRL vs. 1 CsA), n = 4 infectious (1 SRL vs. 3 CsA), n = 7 unknown (5 SRL vs. 2 CsA); 1 accident (CsA), n = 1 pulmonary embolism (SRL).

Graft survival {#sec020}
--------------

Graft survival was not significantly different between treatment arms. Actuarial five-year graft survival was 87.6% (SRL: 89.6% vs. CsA: 85.7%) and ten-year graft survival was 60.2% (SRL: 68.8% vs. CsA: 52.0%). There was a trend towards a reduced graft failure rate under SRL (11.6% SRL vs. 23.9% CsA). Beginning at 8--9 years after the transplantation, Kaplan-Meier curves show a particularly increased death censored failure rate for the CsA treated patients (p = 0.064, [Fig 4](#pone.0234396.g004){ref-type="fig"}). The median was not yet reached in both treatment arms. Graphical and numerical methods were applied for checking the adequacy of the Cox regression model and the decision finally based on the Kolmogorov-type supremum test based on 1,000 simulations. With P = 0.1040 the assumption of proportional hazards can be accepted.

![Kaplan-Meier curve on death censored graft survival.\
Failure rates were 8/69 in the SRl and 17/71 in the CsA Group. Hazard ratio for SRL (95%CI): 0.461 (0.199--1.069).](pone.0234396.g004){#pone.0234396.g004}

A Cox proportional hazard model revealed a 0.461 times smaller hazard in the SRL group compared to CsA ([S4 Table](#pone.0234396.s015){ref-type="supplementary-material"}; 95% CI; 0.199--1.069). There was no relevant difference for the actuarial DCGS five years after the transplantation (SRL: 93.9% vs. CsA 90.9%). This changed for the ten-year analysis where the benefit under SRL almost reached statistical significance (SRL 81.8% vs. CsA 56.4%).

Adverse events {#sec021}
--------------

The adverse events were recorded for the n = 71 patients who had appeared for a control visit and delivered a blood sample. Proteinuria was recorded for n = 10 patients, n = 3 for SRL and n = 7 for CsA (p = 0.17). There was no difference for combined biopsy proven and suspected acute rejections between the two treatment arms (0% SRL vs. 8.6% CsA; p = 0.1; [Table 8](#pone.0234396.t008){ref-type="table"}). There was no significant difference for infections, cardiovascular events or metabolic disorders. Malignancy occurred in n = 1 (2.6%) under SRL and in n = 5 (15.2%) under CsA, (p = 0.09). For those patients remaining on therapy (SRL n = 12 vs. CsA = 22) there was no malignancy recorded under SRL vs. n = 5 under CsA (p = 0.06). With respect to the other adverse events no significant further findings could be reported, likely due to the low numbers.

10.1371/journal.pone.0234396.t008

###### Adverse events.

![](pone.0234396.t008){#pone.0234396.t008g}

                          SRL N = 38 (%)   CsA N = 33 (%)   P-value
  ----------------------- ---------------- ---------------- ---------
  Proteinuria             3 (7.9)          7 (21.2)         0.1712
  Malignancy              1 (2.63)         5 (15.15)        0.0900
  Acute Rejections        0 (0.00)         3 (9.09)         0.0955
  Infections              9 (23.68)        7 (21.21)        1.0000
  Cardiovascular events   8 (21.05)        3 (9.09)         0.2022
  Metabolic disorders     5 (13.16)        4 (12.12)        1.0000

Adverse events are reported here only for the extended follow up after the M36 visit.

Discussion {#sec022}
==========

Many trials exist comparing the effects of an early switch to mTOR-Is with a CNI-based immunosuppression \[[@pone.0234396.ref018]--[@pone.0234396.ref026]\]. Irrespective of the type of the mTOR-I, most of these trials confirm an improved renal function especially in those patients who remain "on therapy" \[[@pone.0234396.ref020], [@pone.0234396.ref021]\] and an efficacy rate in terms of acute rejection, graft and patient survival which is similar to that of CNIs. Besides, the rate of certain malignant and viremic diseases is reduced \[[@pone.0234396.ref027], [@pone.0234396.ref028]\]. However, not all trials could report a favorable outcome especially in earlier times, when higher trough levels and loading doses were used and the experience with side effects was limited \[[@pone.0234396.ref005], [@pone.0234396.ref029]--[@pone.0234396.ref031]\].

One challenge of the current times is the acquisition of reliable "long-term" data reaching beyond the reported half-lives of the grafts. The question for example, if the improved transplant function and the antiproliferative effect with less CAN \[[@pone.0234396.ref032], [@pone.0234396.ref033]\] under mTOR-Is will ultimately translate into a prolonged transplant survival remains unclear to this date.

Here, we present follow-up data on a randomized controlled multicenter trial on renal transplant patients receiving SRL after a short course of CsA (up until 21 days). Of the original ITT cohort (n = 140 randomized patients), n = 71 patients with functioning grafts delivered blood samples with information on dnDSA and transplant function 8.7 years on average after the transplantation.

Primary focus was the analysis of donor specific HLA antibodies. Humoral immunity plays a dominant part for deterioration of graft function and graft loss \[[@pone.0234396.ref012], [@pone.0234396.ref034]\]. Preexisting DSA predispose for early antibody-mediated rejection and poorer graft survival \[[@pone.0234396.ref015]\]. Following renal transplantation DSAs have been shown to develop de novo in 13--27% of previously non-sensitized patients, mostly within the first year but also many years thereafter \[[@pone.0234396.ref035], [@pone.0234396.ref036]\]. De novo DSA are also associated with antibody-mediated rejection (AMR), chronic allograft dysfunction and diminished allograft survival \[[@pone.0234396.ref013], [@pone.0234396.ref037], [@pone.0234396.ref038]\]. In particular, antibodies binding the complement fraction C1q, which is the first step in the activation of the classic complement cascade, have been shown to be a risk factor for the development of AMR \[[@pone.0234396.ref039]\].

In this trial we screened the sera of n = 71 patients for the presence of HLA-antibodies by means of SAB and additionally we tested the C1q-binding capacity of HLA-antibodies. We observed that n = 21 (30%) patients had HLA-antibodies and C1q-binding capacity could be confirmed in n = 10. The incidence of non-complement-binding and complement-binding HLA-antibodies in our study population was within the range of previously published reports \[[@pone.0234396.ref040], [@pone.0234396.ref041]\]. In accordance with our previous report we observed no statistically significant difference between C1q-binding and C1q-non-binding HLA-antibodies \[[@pone.0234396.ref040]\]. There was also no statistical difference in HLA-antibody positivity in the SRL and the CsA group (SRL 24% vs. CsA 36%, p = 0.16). De novo DSA were found in n = 14 (20%). Numerically, there were less dnDSA positive patients under SRL (5/38, 13.2%) compared to CsA (9/33, 27.3%) closely missing significance (p = 0.09). The results are mixed to this in the literature. Some trials reported a higher incidence of dnDSA under mTOR-Is \[[@pone.0234396.ref016], [@pone.0234396.ref042]--[@pone.0234396.ref045]\] and some did not \[[@pone.0234396.ref018], [@pone.0234396.ref046], [@pone.0234396.ref047]\]. The largest multicenter study to date comparing mTOR-Is with CNIs following renal transplantation (TRANSFORM) showed no negative effect for the mTOR-I in terms of dnDSA incidence and antibody-mediated rejection at 12 months \[[@pone.0234396.ref018]\]. When citing these trials, one has to be aware that a more sophisticated HLA-matching on the epitope level (eplet) would probably add further information to the choice of the maintenance immunosuppression in this regard.

We found a significant correlation between dnDSA positivity on impaired graft function when antibodies were directed against HLA-class II antigens (p = 0.01). This effect is in line with previously published data \[[@pone.0234396.ref048]\].

Results showed no significant difference in patient and graft survival. The latter, however, deserves further consideration. The actuarial 5-yr DCGS showed no difference between the two groups (SRL: 93.9% vs. CsA 90.9%). Kaplan-Meier curve of the DCGS shows a deterioration of the CNI- but not the mTOR-I-treated grafts beginning at around month 90--100 as one would expect according to the known half-lives of \~9--10 years. And the actuarial 10-yr- DCGS shows a trend towards a better survival under SRL (81.8% SRL vs. 56.4% CsA) averaging 68.3%. It is difficult to find reliable long-term data for a comparison. Our data correspond well to the latest OPTN/SRTR report. Here, the 10-yr graft survival was 48.4% (compared to 68.8% SRL and 52.0% CsA in our trial) \[[@pone.0234396.ref001]\]. Unfortunately, the report did not distinguish between the different immunosuppressants. For a better comparison this would have been helpful because only a minority had received a CsA- (1.7%) or an mTOR-I- (1.9%) based immunosuppression \[[@pone.0234396.ref001]\]. A single center trial with a follow-up of 7 yrs reported a substantially better actuarial 10-year graft survival of 63.5% and a DCGS of 77.5% for a CsA/MMF combination even without steroids \[[@pone.0234396.ref033]\]. But yet again, these results seem difficult to compare with because there were substantial differences in trial design, induction therapy and the percentage of living donation (71.5% vs. 5.7%).

Transplant function was shown to be superior in the SMART-trial under SRL 12 and 36 months after Tx \[[@pone.0234396.ref003], [@pone.0234396.ref019]\]. This could once again be confirmed in the current analysis at 104±8.8 months. On average, renal function had remained excellent in the SRL arm with an eGFR of 64.37±26.44 ml/min/1.73 m^2^ which had even slightly improved compared to the measurement of month 3 after the transplantation. For those patients who had remained "on therapy" GFR was even better with 66.00 ± 15.25 ml/min/1.73 m^2^. This is in accord with other publications which report that patients seem to benefit in particular when they remain "on therapy" \[[@pone.0234396.ref021], [@pone.0234396.ref049], [@pone.0234396.ref050]\]. In contrast, GFR had significantly deteriorated under CsA. Although difficult to compare for existing differences regarding the mTOR-I used, medication plan and study duration, these results appear similar to other trials with "longer" follow-ups, such as the ZEUS- or HERAKLES- 5-yr extension trials \[[@pone.0234396.ref021], [@pone.0234396.ref049]\]. Interestingly, decrease of transplant function under CNIs seems to occur well beyond the first 5 years \[[@pone.0234396.ref033], [@pone.0234396.ref050]\].

Benefits of an mTOR-I therapy regarding malignancy have been uniformly confirmed and recently shown to extend beyond skin cancers \[[@pone.0234396.ref027]\]. Thus, the results from this trial could be expected.

A limitation for this study is that 49% of the original study population could not be included for the analysis of DSAs. As outlined in the results section, most of these patients had either died, lost their graft or declined participation. Nonetheless, most of the relevant clinical information on these patients could still be gathered by retrospective chart review and contact of their primary care physicians and the patients themselves. With n = 4 in the SRL arm und n = 9 of the CsA the number of those who were actually "lost to follow-up" was much lower and appear acceptable considering the long follow-up.

Lack of tolerability remains an important aspect for the use of mTOR-Is and is another limitation of this trial. Only 31.6% (12/38) once randomized to receive SRL compared to 66.7% (22/33) started on CsA were still on the original immunosuppressant. The majority had stopped the SRL relatively early as only 40.6% had remained "on therapy" after the first 3 years. The first patients had been randomized by 2006 when the experience with mTOR-I side effects was low. This is an important aspect since many of these drug discontinuations would not have been pursued nowadays. Nonetheless, problems with the mTOR-I tolerability remain up to this day \[[@pone.0234396.ref018]\] and clinical experience is needed for a successful management. Patients in both treatment arms were usually switched to Tacrolimus. Even though the percentage of patients switched from SRL to TAC was higher compared to those switched from CsA, the overall exposure time to TAC was not significantly different between the groups. Another limitation specifically concerning our data on HLA-antibodies is that only a single measurement of HLA-antibodies in the post-transplant follow-up was used. Nonetheless, our data correlated well to the existing evidence. Lastly, we do not have data from histopathology to corroborate our findings.

In conclusion, we could show no difference for the occurrence of DSAs under SRL compared to CsA. The data confirmed an impaired graft function in the presence of DSAs. Graft function had remained significantly better under SRL vs. CsA with stable eGFR only under SRL compared to month 3 after the transplantation. Due to the long follow-up we could observe the expected gradual decline in graft survival under CsA and unexpectedly saw a benefit for the SRL therapy which did not become apparent until late in the observation period (8--9 yrs after Tx). Further trials with reliable long-term data will have to confirm our findings.
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CAN

:   chronic allograft nephropathy

CIT

:   cold ischemia time

CNI

:   Calcineurininhibitor

CsA

:   Ciclosporin A

DCGS

:   death censored graft survival

DGF

:   delayed graft function

DSA

:   donor specific antibody

eCrCl

:   estimated creatinine clearance

GFR

:   glomerular filtration rate

HLA

:   human leucocyte antigen

MFI

:   mean fluorescence intensity

OPTN

:   Organ Procurement and Transplantation Network

PRA

:   panel reactive antibody

SAB

:   single antigen beads

sCr

:   serum creatinine

SRL

:   Sirolimus

Tk

:   Time of conversion

10.1371/journal.pone.0234396.r001

Decision Letter 0

Gołębiewska

Justyna

Academic Editor

© 2020 Justyna Gołębiewska

2020

Justyna Gołębiewska

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

10 Dec 2019

PONE-D-19-25265

Early conversion to a CNI-free immunosuppression with SRL after renal Transplantation -- long-term follow-up of a multicenter trial

PLOS ONE

Dear Prof. Dr. Andrassy,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR:

The manuscript is of potential interest to the renal transplant community. However, it is not acceptable for publication in its current form. The major limitation of the study is a substantial drop-out rate and considerable tacrolimus exposure in both groups. Therefore additional data should be provided and discussion expanded:

The Authors should evaluate and compare the mean time with tacrolimus exposure in SRL vs CsA arm. Why were so many patients switched to tacrolimus?  A small table listing the reasons would be informative. Just listing late adverse events is not as informative as listing those that caused a change in drug delivery.Data on proteinuria in both groups should be provided.The Authors should highlight the limitations of the very low rate of patients on the original immunosuppression at the end of 8-9 years follow-up.The conclusions about dnDSA must consider that the majority of the patients were in use of tacrolimus that was not the original immunosuppression.The absence of histology of the grafts also limits the ability to make firm conclusions on the impact of CNI free status on graft stability, this limitation should be provided as well.

Additionally, please provide corrections according to the statistical Reviewer suggestions (Reviewer 6).

==============================

We would appreciate receiving your revised manuscript by Jan 23 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Justyna Gołębiewska

Academic Editor

PLOS ONE

Journal Requirements:

**When submitting your revision, we need you to address these additional requirements:**

**Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>**Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (1) whether consent was suitably informed and (2) what type you obtained (for instance, written or verbal). If your study included minors under age 18, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.In your Methods section, please provide additional information regarding the donated tissues or organs used in the study. Please specify whether the study involved the use of donated tissue/organs from any vulnerable populations, and provide information on the consent given by the donor or their next of kin. Examples of vulnerable populations include prisoners, subjects with reduced mental capacity due to illness or age, and children. If such a population as used, please ensure you have describe the population and justify the decision to use tissue/organ donations from this group. If not, please state in your Ethics Statement, \'None of the transplant donors were from a vulnerable population and all donors or next of kin provided written informed consent that was freely given.\'Thank you for including your ethics statement:  \"This trial was conducted according to GCP guidelines and the declaration of Helsinki and was approved by the local ethics committees of the participating centers.\"

a.Please amend your current ethics statement to include the full name of the ethics committee/institutional review board(s) that approved your specific study.

b.Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the "Ethics Statement" field of the submission form (via "Edit Submission").

For additional information about PLOS ONE ethical requirements for human subjects research, please refer to <http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research>.

5\. Please amend the manuscript submission data (via Edit Submission) to include author Andreas Pascher.

6.Thank you for stating the following in the Financial Disclosure section:

J. A. received funding from an unrestricted medical grant by Pfizer Pharma GmbH to perform this trial.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

We note that you received funding from a commercial source: Pfizer

Please provide an amended Competing Interests Statement that explicitly states this commercial funder, along with any other [relevant declarations](http://www.plosone.org/static/competing.action) relating to employment, consultancy, patents, products in development, marketed products, etc.

Within this Competing Interests Statement, please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: \"This does not alter our adherence to PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your amended Competing Interests Statement within your cover letter. We will change the online submission form on your behalf.

7. 

We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>.

In your revised cover letter, please address the following prompts:

a\) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b\) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see <http://www.bmj.com/content/340/bmj.c181.long> for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>.

We will update your Data Availability statement on your behalf to reflect the information you provide.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

Reviewer \#3: Partly

Reviewer \#4: No

Reviewer \#5: Partly

Reviewer \#6: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: No

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

Reviewer \#5: Yes

Reviewer \#6: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: No

Reviewer \#4: Yes

Reviewer \#5: No

Reviewer \#6: Yes

\*\*\*\*\*\*\*\*\*\*
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Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This is long-term data about the SMART study. This study aims to evaluate the eGFR in patients early converted to CNI-free immunosuppression with SRL after renal Transplantation. The authors discussed that were few studies with long term outcome about CNI-free immunosuppression.

This is a well writing manuscript with an extended follow-up of the primary study. The extension aims to evaluate the development of de novo donor-specific antibodies (dnDSA). This is a relevant question because the immunosuppression without CNI was associated with higher rates of dnDSA. A serious limitation was the sample size with very low patients in use of the original immunosuppression (31.6% in the sirolimus and 66.7% in the ciclosporin)

Main Questions:

1\. Possible the good results of early convesion to sirolimus was related to the induction therapy with thymoglobulin. This type of induction therapy diverges from other CNI-convertions trials. The authors should highlight this point. Additionally, the use of a loading dose of sirolimus is not common practice today.

2\. Measures of dnDSA. The authors show that there were no differences in dnDSA between the ciclosporin and the sirolimus group. However, this could be analysed with caution because only 31.6% of patients in the sirolimus group were in use of the original immunosuppression. The majority of the patients were switched to tacrolimus. The authors should evaluate the mean time with tacrolimus exposure.

3\. Transplant Function. The low sample size does not allow to show better renal function in the sirolimus group. Only the Nankivell formula in the ITT and on the therapy population showed the difference. I suggest the conclusion based only the more contemporaneous formula as MDRD. Addictionally, the analysis should be done by mixed models. This type of analysis consider the repeated measures of the data.

The best method is as longitudinal data analysis of covariance with na interaction between time and the treatment variable.

Ref: Different ways to estimate treatment effects in randomised controlled trials. Contemp Clin Trials Commun. 2018 Mar 28;10:80-85.

4\. Survival analysis: The plots of graft and patient survival seems to violate the proportional Hazard assumption. The Schoenfeld Residuals Test should be done to test the proportional assumption. A more complex model should be used to incorporate the diferences in event-proportions during the follow-up like a time-dependent proportional Cox Model. The conclusion of better graft survival in the sirolimus group must be done by a Time Dependent Cox Model.

Ref: Time-dependent covariates in the Cox proportional-hazards regression model. Fisher LD. Annu Rev Public Health. 1999;20:145-57.

5\. Discussion. The authors should highlight the limitations of the very low rate of patients on the original immunosuppression at the end of 8-9 years follow-up. The conclusions about dnDSA must consider that the majority of the patients were in use of tacrolimus that was not the original immunosuppression.

The conclusion about better renal function in the sirolimus group should be re-analysed based on eGFR by MDRD or CKD-EPI. The conclusion about graft survival probably needs a Cox Model.

Reviewer \#2: This is the long-term extension of a previous RCT aimed at evaluating early full conversion from a CNI- to an mTORi-based immunosuppressive protocol as compared with standard CNI-based immunosuppression in KTRs. Main findings of this study are that dnDSA developed similarly in both groups, and long-term renal graft function was better in SRL than in CNI, even though discontinuation rate was significantly higher under mTORi.

The manuscript is of interest for the audience of clinicians involved in the field of kidney transplantation, and findings refer to a very prolonged follow-up. Moreover it is well-written and statistical approach is robust.

However, it lacks originality, since main findings has been previously reported in larger cohorts. Moreover, full conversion from CNI to mTORi appears an old approach, since most studies aimed at addressing the protective role of mTORi on graft function are designed in order to compare mTORi and low exposure CNI vs standard exposure CNI therapy. Last, SRL vs CsA appears also a dated protocol comparison.

Other points:

As correctly acknowledged by the AA a veray graet incidence of drop-out is a limitation (about 50% of the original cohort), since can significantly affects reliability of results.

Is there any relationship between dnDSA development and eGFR changes over time? Indeed AA only present data on the relationship of endpoint eGFR and dnDNA.

Was AR, whose incidence was greater in the CsA group, associated with dnDSA development and/or graft survival?

Any data on proteinuria in the mTORi group?

Reviewer \#3: This study reported long term results of the SMART trial (CNI free immunosuppression of SRL, MMF and Pred compared to CsA, MMF and Pred). The results also included development of denovo DSA in addition to GFR, graft and patient survival.

There is significant drop out which is reasonable for this long term observational study, however the reasons for drop out are not addressed or explained. The therapy discontinuation in the Sirolimus group is significantly high compared to the controls (21% vs 66%), which would impact on the final conclusions. The number of patients with donor specific HLA Abs are also small to make a significant conclusion (5 vs 9), however as noted there is no impact type of immunosuppression on dnDSA.

The univariate analysis does not identify any significant risk factor as this study was a long term observation which by default had survived the worse outcomes irrespective of the risks and thus is a selection bias. This aspect or limitation should be explained in the discussion. The benefits of sirolimus in preserving GFR and long term graft survival is demonstrated again in this follow up.

I would recommend addressing these limitations in the discussion and also revising the the language in the Introduction and Discussion sections to conventional manuscript format.

Reviewer \#4: This study describes the long-term results (about 9 years) of SMART-Trial, focusing on the development of dnDSA.

Despite the widespread importance of knowing long-term efficacy and safety results of immunosuppressive strategies with mTOR inhibitors, some aspects should be pointed out:

1\. The strategy used in SMART-Trial was promising in 2006, but it is currently an exception immunosuppressive regimen: CsA instead of TAC + preemptive conversion rather than mTORi de novo + loading-dose SRL. This makes these results less interesting today.

2\. Focusing on dnDSA as the primary objective, trying to correlate the results with the immunosuppressive regimen, does not seem appropriate, since:

a\) Only 34 of 140 patients originally enrolled were on therapy.

b\) Over such a long follow-up period, many non-evaluated variables may interfere on results, such as: drug conversions, immunosuppression exposure (doses/concentration / variability), and compliance with treatment.

c\) There is no information on pre-formed DSA, which makes it difficult to conclude that a first measured DSA is de novo.

I believe a more complete descriptive analysis of efficacy and safety aspects of the 140 patients originally enrolled in SMART trial would be most useful.

Minor issues:

1\. I suggest inserting the legends of abbreviations used in the tables and figures

2\. I suggest pre-define the abbreviations used throughout the text: Tx, n.s., pts, Abs, SCr-Tk+7, CAN, DCGS, etc

3\. I suggest caution in concluding on renal function based on formulas not used today, as Cockroft-Gault and Nankivell.

4\. I suggest adjusting the analysis of renal function for deaths, graft losses and follow-up losses.

5\. I suggest to pre-define the adverse events listed in Table 7.

6\. I suggest that the Discussion session should not be used to repeat results but for critical analysis of study findings.

7\. I suggest improving Figure 1 to better demonstrate how many and when patients died, lost their grafts, lost the follow-up and discontinued drugs.

Reviewer \#5: The authors updated a German RCT (SMART Trial) with about half (71/140) of the original study group. Blood samples were obtained an average of 8.7 years after initial enrollment in order to screen for the development of DSA. They concluded that "An early conversion to SRL does not result in an increased incidence of dnDSA nor increased long-term risk for the recipient. Transplant function remains improved with benefits for the graft survival." The important signals reported for the studied survivors were no significant increase in DSA (SRL 5/38, 13.2% vs. CsA 9/33, 27.3%; P=0.097) with an improved eGFR (SRL 64.37 vs. CsA 53.19 ml/min/1.73m2, p=0.044), for those converted to sirolimus. Additional signals that are very encouraging were trends to lower rates of de novo cancers and perhaps fewer viral infections.

In many prior trials using mTORi based immunosuppression to reduce or eliminate CNI drugs very good outcomes were reported for those that tolerated the mTORi. However, prior trials were often plagued by dropouts and investigator switches off the mTORi drugs for various side effects including oral lesions, dyslipidemia, edema, lymphoceles, wound disruptions/hernias, GI intolerance, etc. Many such switches seemed arbitrary and inconsistent, and in effect prevented the formation of firm conclusions from many well-designed trials.

1\. While offering some reassuring long-term data that DSA formation is not excessive for those recipients remaining on an mTORi in a CNI free regimen, this sub study only reports 31% of the SRL recipients still taking the drug, and many were on another CNI. So again, why were so many switched? A small table listing the reasons would be informative. Just listing late adverse events is not as informative as listing those that caused a change in drug delivery.

2\. No doubt many of the switches off SRL were done due to the side effects caused similarly by mycophenolate mofetil; especially bone marrow suppression and GI intolerance. This should also be noted.

3\. Any critical analysis of long-term renal allograft function, especially on an mTORi requires demonstration of the presence and magnitude of proteinuria. I found no such data which is a major limitation of this paper. This should be provided, at least UA dipsticks, or featured as a major limitation.

4\. In addition to \#3, the absence of histology of the grafts also limits the ability to make firm conclusions on the impact of CNI free status on graft stability, This limitation should be provided as well.

Reviewer \#6: This paper looks at a long term follow-up of a clinical trial. Roughly half the patients originally enrolled are available for this follow-up study - the most common reasons for not being in the long-term follow-up study are death and progression.

It is reassuring to note there appears to be no differential dropout by arm; but it would also be useful in Table 1a to look at the comparison of the ITT group and the long-term group, because this will show how the trial population has changed over time.

Please do not use p=n.s. but give actual p-values in the text as they are there in the Tables. The precision should be the same also - 1sf below p=0.01 is fine.

In Table 5-6 there are clear differences between arms in the \"on therapy\" population - I think these figures should be given in summary only and not tested given the known imbalance (p=0.004) identified earlier - this would invalidate the underlying statistical assumption.

Please give HR & CI for survival to see if this is evidence of lack of effect or lack of evidence of effect. Similarly for graft survival - if p\<.05 represents significance then please do not talk of trends to wards or differences when p\>.05.

Figure 3 and 4 require total numbers of events per arm to show the power to detect a difference.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Luis Gustavo Modelli de Andrade

Reviewer \#2: No

Reviewer \#3: No

Reviewer \#4: No

Reviewer \#5: No

Reviewer \#6: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Please find my response to the editor\'s and reviewers\'s request uploaded (Andrassy SMART response.doc) along with the revised version of the manuscript
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Early conversion to a CNI-free immunosuppression with SRL after renal Transplantation -- long-term follow-up of a multicenter trial

PLOS ONE

Dear Prof. Dr. Andrassy,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR:

Please address all issues pointed out by Reviewers 4 and 5.

Please provide a more detailed analysis of the subgroup of patients maintained on SRL-MMF-Cs for the 8 years

==============================

We would appreciate receiving your revised manuscript by May 25 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Justyna Gołębiewska

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

Reviewer \#3: All comments have been addressed

Reviewer \#4: (No Response)

Reviewer \#5: (No Response)

Reviewer \#6: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Partly

Reviewer \#5: Yes

Reviewer \#6: (No Response)

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

Reviewer \#5: Yes

Reviewer \#6: (No Response)

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

Reviewer \#5: No

Reviewer \#6: (No Response)

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

Reviewer \#5: Yes

Reviewer \#6: (No Response)

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: I considered that the authors address all the suggestions. The statistic corrections were made. Also, the limitations were discussed in more detail. I considered that the manuscript may be considered for publication in the current revised form.

Reviewer \#2: The AA adequately addressed all the concerns raised by this reviewer.

The manuscript was significantly improved

Reviewer \#3: The authors have addressed the criticisms about the dropouts in their revision and also explained in the reason for lack of data on proteinuria after 36 months. The manuscript has also been changed to meet the conventional format. The authors have also changed the estimation of GFR to CKD-epi and MDRD. This study has merit in terms of the long follow up, and the limitation would be as mentioned buy the authors the analysis of DSAs was limited to 49% of the study population.

Reviewer \#4: Authors have clarified several points raised by reviewers.

They also included important information in the text.

My adicional comments are attached.

Reviewer \#5: The authors have provided extension data from a prior RCT termed SMART including 71 of the original ITT 140 kidney transplant recipients with a mean 8.7 year follow-up. The aim of this extension was to detect de novo DSA formation comparing those on a CNI free regimen after a 3-week switch from CsA to Sirolimus to those that remained on CsA; for each MMF/Cs continued. They report that a statistically significant increase in dnDSA was not detected (SRL 5/38, 13.2% vs. CsA 9/33, 27.3%; P=0.097) and GFR remained improved under SRL with (64 vs. 53 ml/min/1.73m2, p=0.044). Although graft failure and skin tumors were less for those on SRL, the difference was not statistically significant. From these data they concluded "An early conversion to SRL does not result in an increased incidence of dnDSA nor increased long-term risk for the recipient. Transplant function remains improved with benefits for the graft survival."

The study and its results, like many other long-term kidney transplant trials, especially including mTORi suffer from incomplete and perhaps unreliable patient selection and retention. To their credit the authors freely point out that the use of mTORi have been plagued by a lack of tolerability for many patients, and the very inconsistent role more peripheral investigators play in drug switching and dose changes. Their rather sober tally of only "31.6% (12/38) once randomized to receive SRL compared to 66.7% (22/33) started on CsA were still on the original immunosuppressant. The majority had stopped the SRL relatively early as only 40.6% had remained "on therapy" after the first 3 years." That said mean 8.7 year follow-up data is about the best one could expect to see and MMF switches and changes can be 50% or more as well. More generalized themes are more likely to be true.

Comments

1\. The paper often uses 3-month for the time of conversion to SRL---wasn't it 3 weeks? Fix this in the narrative.

2\. Fix your Figure 1 flow sheet and list how many were on sirolimus-MMF-Cs and how many were on CNI-MMF-Cs. How many were truly CNI-free?

3\. Those who remain CNI-free on an mTORI usually demonstrate a statistically significant reductions in both skin and other cancers over time, especially after 3 years. The lack of significance in your study, I speculate, is due to the very few that are CNI-free and the larger numbers that switched back to a CNI. Comment.

4\. The Discussion should add a comment that dnDSA may have more to do with the stringency of HLA mismatches rather than the choice of maintenance immuno-suppression. The emerging powerful message from eplet matching would seem to support this hypothesis. AJT 2013; 13: 3114--3122 and JASN 2017; 28: 3353--3362.

5\. The authors really need to cull out the 40% or so that began and remained on SRL-MMF-Cs for the 8 years. What were their eGFR and urine protein excretion? How many experienced biopsy confirmed rejection and did any of these develop cancer?

Reviewer \#6: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Dear Dr. Andrassy,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Justyna Gołębiewska

Academic Editor

PLOS ONE
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1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed
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Reviewer \#4: All comments have been addressed

Reviewer \#5: All comments have been addressed

Reviewer \#6: All comments have been addressed
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2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.
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3\. Has the statistical analysis been performed appropriately and rigorously?
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Reviewer \#4: Yes

Reviewer \#5: Yes

Reviewer \#6: (No Response)
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4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.
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5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.
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Reviewer \#3: Yes

Reviewer \#4: Yes

Reviewer \#5: Yes
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6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: All comments have been answered by the authors. I considered the manuscript suitable for publication in the present form.

Reviewer \#2: The Authors adequately addressed all queries raised by the Reviewers and manuscript is significantly improved

Reviewer \#3: The authors have addressed the comments regarding statistical changes and made necessary changes to the manuscript. I am of the opinion that the manuscript be considered for publication in the current format.

Reviewer \#4: The authors addressed all questions/concerns raised by the reviewer.

Manuscript sounds suitable to be published in that format.

Reviewer \#5: I appreciate the detailed additions made by the authors to update the actual data collected. The long-term followup does add substantial new information to the original study.
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Dear Dr. Andrassy:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Justyna Gołębiewska

Academic Editor

PLOS ONE
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